GLPwatch
Papers (12034)
Page 64 of 201, ranked by citation count.
- Tendency of Semaglutide to Induce Gastroparesis: A Case Report.
- A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study).
- Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications.
- Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS).
- Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight people with type 1 diabetes.
- Lower Risk of Postoperative Complications and Rotator Cuff Retear Associated With Semaglutide Use in Patients with Type II Diabetes Mellitus Undergoing Arthroscopic Rotator Cuff Repair.
- Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes.
- Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
- Tirzepatide alleviates doxorubicin-induced cardiotoxicity via inhibiting HRD1-mediated Nrf2 ubiquitination.
- Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats.
- Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy.
- Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials.
- Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes.
- Factors Associated With Semaglutide Initiation Among Adults With Obesity.
- 18F-radiolabeled GLP-1 analog exendin-4 for PET/CT imaging of insulinoma in small animals.
- Effects of Semaglutide and Empagliflozin on Inflammatory Markers in Patients with Type 2 Diabetes.
- Liraglutide blocks the proliferation, migration and phenotypic switching of Homocysteine (Hcy)-induced vascular smooth muscle cells (VSMCs) by suppressing proprotein convertase subtilisin kexin9 (PCSK9)/ low-density lipoprotein receptor (LDLR).
- Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.
- Pregnancy Outcomes After Semaglutide Exposure.
- Exenatide improves excessive daytime sleepiness and wakefulness in obese patients with type 2 diabetes without obstructive sleep apnoea.
- Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats.
- Exendin-4 improves cardiac function in mice overexpressing monocyte chemoattractant protein-1 in cardiomyocytes.
- The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
- Attempted suicide with liraglutide overdose did not induce hypoglycemia.
- Assessment of the cardioprotective effect of liraglutide on methotrexate induced cardiac dysfunction through suppression of inflammation and enhancement of angiogenesis in rats.
- Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.
- Safe Continuation of Glucagon-like Peptide 1 Receptor Agonists at Endoscopy: A Case Series of 57 Adults Undergoing Endoscopic Sleeve Gastroplasty.
- Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).
- Combined therapy of mesenchymal stem cells with a GLP-1 receptor agonist, liraglutide, on an inflammatory-mediated diabetic non-human primate model.
- Exendin-4 overcomes cytokine-induced decreases in gap junction coupling via protein kinase A and Epac2 in mouse and human islets.
- Exendin-4 restores glucolipotoxicity-induced gene expression in human coronary artery endothelial cells.
- Peptide GLP-1 receptor agonists: From injection to oral delivery strategies.
- EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS.
- Sweetening the deal: an infodemiological study of worldwide interest in semaglutide using Google Trends extended for health application programming interface.
- Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide.
- Site-specific fatty chain-modified exenatide analogs with balanced glucoregulatory activity and prolonged in vivo activity.
- Exenatide induces an increase in vasodilatory and a decrease in vasoconstrictive mediators.
- Recent advances in peptide-based therapies for obesity and type 2 diabetes.
- Glucagon-like peptide-1 receptor agonists and kidney outcomes.
- Effects of the multilayer structures on Exenatide release and bioactivity in microsphere/thermosensitive hydrogel system.
- Inhibition of microRNA-124a attenuates non-alcoholic fatty liver disease through upregulation of adipose triglyceride lipase and the effect of liraglutide intervention.
- Semaglutide effects on energy balance are mediated by Adcyap1<sup>+</sup> neurons in the dorsal vagal complex.
- Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study.
- Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates.
- Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes.
- Energy intake as a short-term biomarker for weight loss in adults with obesity receiving liraglutide: A randomized trial.
- Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin.
- Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
- Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients.
- Post-translational regulated and hypoxia-responsible VEGF plasmid for efficient secretion.
- Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.
- Semaglutide for the Treatment of Type 2 Diabetes Mellitus.
- Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
- Weight loss effect of liraglutide in real-life: the experience of a single Italian obesity center.
- Liraglutide ameliorates gentamicin-induced acute kidney injury in rats via PGC-1α- mediated mitochondrial biogenesis: Involvement of PKA/CREB and Notch/Hes-1 signaling pathways.
- Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis.
- Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study.
- Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes.
- Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
- Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.